Slide 1: FDC Limited Investor Presentation Q2FY23
FDC LIMITED Investor Presentation Q2FY23 www.fdcindia.com 1
Slide 2: Disclaimer
DISCLAIMER This report may contain certain statements that might be considered forward looking. These statements are subject to certain risk and uncertainties, since they are based on certain assumptions and expectations of future events. Actual results may differ materially from those expressed in
Slide 3: Platform to deliver sustainable value
Platform to deliver sustainable value 1 2 3 Best-in-class manufacturing Strong Domestic Business facilities & regulatory Strong Financials ✓ Multiple levers, high growth track record brands to anchor growth ✓ Portfolio of high quality ✓ High Return on Capital ✓ Zifi – Category Creator in manufacturi
Slide 4: Multiple Levers to drive growth
1(a) Multiple Levers to drive growth (Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022) Q2FY23 5% Anti-Infectives 3%1% GI 3% 4% VMN Revenue 5% 34% Derma Mix Domestic, 83% Ophthal 7% Cardiac Export, 17% Gynaec. 9% Respiratory Antiviral Others 29% Domestic Sales Export Sales 25% 26% 102% 56% 5
Slide 5: Multiple Top Brands to anchor growth
1(a) Multiple Top Brands to anchor growth Brand Molecule Rank Rs. Crs MS % Electral Oral Electrolytes ❶ 350 74.2% Zifi Cefixime ❶ 320 24.7% Enerzal Energy Drinks ❶ 151 42.5% Vitcofol Folic acid + Cyanocobalamin + Nicotinamide ❽ 86 2.6% Zifi CV Cefixime + Clav. ❶ 75 46.2% Zathrin Azithromycin ❹ 59 4.
Slide 6: Electral – Category Creator & Consistent Leader in Oral Rehydration Salts
1(b) Electral – Category Creator & Consistent Leader in Oral Rehydration Salts Electral –Brand synomous with product category In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Sep 20 Market Share in MAT Sep 22 13.6% 12.9% 74.4% 71.8% 74.2% 2.9% 3.7
Slide 7: Zifi – Category Leader in Cefixime
1(c) Zifi – Category Leader in CEFIXIME Zifi – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Sep 20 Market Share in MAT Sep 22 22.5% 23.1% 23.9% 24.8% 24.7% MAT Sep 20 MAT Sep 21 MAT Sep 22 5.5% 5.7% 5.7% 6.4% 5.5% 4.
Slide 8: Enerzal – Category Leader in Energy Drinks
1(d) Enerzal– Category Leader in Energy Drinks Enerzal – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Sep 20 Market Share in MAT Sep 22 26.6% 23.3% 42.8% 40.1% 42.5% 16.7% 16.0% 14.1% MAT Sep 20 MAT Sep 21 MAT Sep 22
Slide 9: Among top Corporates in IPM in Prescriptions at Core Specialties
Among top 20 Corporates in IPM in Prescriptions at Core Specialties in H1 (Apr-Sep YTD) 1e) % Growth Specialities FDC IPM % MS Rank Overall 51 47 5.6 13 GP-NON.MBBS 47 41 9.7 4 GP - MBBS 65 38 7.2 9 PEDIATRICIAN 76 72 5.7 16 ENT SPECIALIST 57 51 5.1 16 OPHTHALMOLOGIST 14 37 5.6 10 (Source: IQVIA-Med
Slide 10: Manufacturing Facilities
2 (a) Manufacturing Facilities Sinnar Sinnar Dosage Form Baddi Goa 1/2 Goa 3 Waluj (Food) (Form) Tablet/Capsule Baddi Dry Syrup Liquid Oral Powder Ophthalmic Ear Drops Sinnar - Food Plant Foods Waluj Sinnar – Form Plant Roha Goa (3 Facilities) API Plant Food Plant Formulation Plant Source: Internal
Slide 11: Top Countries: Export Sale of APIs & Formulations Q2FY23
2 (b) TOP 10 Countries: Export Sale of APIs & Formulations Q2FY23 Export Formulation Sales - 58Crs Export API Sales - 17crs 13% USA 16% Germany 2% 21% New Zealand Japan 3% UK USA 3% Chile Saudi Arabia 3% Malaysia Turkey 4% 14% 3% Kathmandu Algeria Ethiopia 4% South Korea 4% 55% Myanmar Taiwan 4% 4%
Slide 12: Quarterly Performance
3(a) Quarterly Performance 45% 11% 13% 6% 8% 5% 3% -6% 332 312 445 396 341 337 493 447 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Sales (in Crs) YOY Sales Growth % 31% 28% 26% 19% 20% 17% 18% 9% 4.18 2.49 5.93 4.36 1.87 0.85 4.37 3.14 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2F
Slide 13: Quarterly Performance
3(a) Quarterly Performance Revenue from operations in crs. (except EPS) Q1FY23 Q1FY22 YoY % Revenue from operations 447 396 13% H1FY22 396 Other income 28 31 -8% Total Income 475 427 11% 12% H1FY23 447 Operating Expenses 396 324 22% EBITDA 79 103 -23% Finance Cost 1.0 0.7 41% Depreciation 10 9 5% EP
Slide 14: For updates and company information, please visit our website
For updates and company information, please visit our website i.e. www.fdcindia.com For specific queries, kindly email on investors@fdcindia.com
Slide 15: Thank YOU
Thank YOU